NRx Pharmaceuticals, Inc.
USD4.05
-0.57 (-12.34%)
CEO
Jonathan C. Javitt
IPO Date
2017-12-04
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Open
$3.61
Prev. Close
$4.62
Day Low
$3.45
Day High
$4.29
52W Low
$1.62
52W High
$5.05
Market Cap
$0.07B
Volume
4.56M
| 100,000 |
| $2.39 |
| 10 Sept 2025 | Javitt Jonathan C | director, 10 percent owner, officer: Chairman and Chief Scientist | A-Award | Acquired | 125,000 | $1.73 |
| 10 Sept 2025 | McBride Dennis | director | A-Award | Acquired | 25,000 | $1.73 |
| 10 Sept 2025 | Hurvitz Chaim | director | A-Award | Acquired | 25,000 | $1.73 |
| 10 Sept 2025 | Flynn Patrick John | director | A-Award | Acquired | 50,000 | $1.73 |
| 21 Aug 2025 | B Group, Inc. | 10 percent owner | Disposed | 0 | $0.00 |
| 11 Feb 2025 | ABRAMS MICHAEL S | Chief Financial Officer | A-Award | Acquired | 50,000 | $2.94 |
| 18 Dec 2024 | Javitt Jonathan C | director, 10 percent owner, officer: Chairman and Chief Scientist | P-Purchase | Acquired | 40,000 | $1.17 |
| 22 Nov 2024 | ABRAMS MICHAEL S | — | Disposed | 0 | $0.00 |